Management Team

 

President/Chief Scientific Officer - Bruce J. Oberhardt, Ph.D.

Dr. Oberhardt has led and/or participated in a number of first-of-a-kind technological developments including “CoaguChek” and founded Cardiovascular Diagnostics: a successful IPO.  Major focus areas have included the development of and consulting in multidisciplinary and disruptive technologies, especially involving: blood, fluidic systems, instrumentation, and medical devices and solving problems associated with the intersection of biomedical technology and business.  He served in management positions for major multinational medical products manufacturers and developed technologies to help in diabetes, blood diseases, cardiovascular disease, and cancer. Products based on these technologies are currently saving patients’ lives daily. 

                                            Scientific Advisors

 

Founder/ Scientific Advisor - Professor Stefan Franzen, Ph.D.

Professor of Chemistry North Carolina State University

Professor Franzen has studied the use of the plant viral nanoparticles for cell targeting applications using confocal, fluorescence and differential interference contrast microscopies.  He has also designed novel modifications of the plant viral nanoparticles for encapsidation, cancer drug packaging and loading of marker proteins for cell signaling experiments.  For the past 10 years he has studied a wide variety of nanoparticle delivery options and published early papers on gold nanopartcle research.

Founder/ Scientific Advisor - Professor Steven Lommel, Ph.D.

Professor of Plant Pathology, Professor of Genetics, Assistant Vice-Chancellor for Research North Carolina State University

Professor Lommel's primary research program is in the areas of plant virology, plant viral pathogenesis and plant genomics. The three research themes comprising the program are: i) the molecular mechanism of plant virus movement.  ii) Structure of the plant virus nanoparticle.iii) The tobacco genome initiative. Professor Lommel has researched the NanoVector nanoparticle for 25 years.

Oncology Advisor - Professor David J. Adams, Ph.D.

Associate Professor of Medicine, Head, Drug Discovery and Development Laboratory Duke Comprehensive CancerCenter

Professor Adams is an experienced, accomplished research scientist with a broad background in anticancer drug discovery and development that spans eleven years in the pharmaceutical industry and eleven years at a renowned academic medical center.  He possess extensive laboratory skills that include cell, tissue and animal models for cancer research as well as numerous analytical techniques for DNA, RNA and protein analysis, chromatography, microscopy and screening technologies based on UV-VIS, fluorescence, chemiluminescence, and liquid scintillation spectroscopy.

                                      NanoVector, Inc.• P.O. Box 98385 • Raleigh, NC27624

                                    Phone: 919.878.8464 • Fax: 919.676.5436

  

Chief Executive Officer - Albert D. Bender, Ph.D.

Dr. Bender has over 20 years as both a large company executive and as founder and CEO of four venture backed startup companies. Three of these were sold for a good investor return. During his career, Dr. Bender has raised 10 rounds of venture capital totaling more than $150M. He also has a working relationship with major venture capital partners in North America. His start-up approach is hands-on and focused on practical, workable solutions that produce measurable results. In his career, Dr. Bender has proven success leading organizations and activities in the areas of business strategy, optimizing business operations, engineering, sales and marketing and raising capital.